Welcome to our dedicated page for Nevro news (Ticker: NVRO), a resource for investors and traders seeking the latest updates and insights on Nevro stock.
Nevro Corp (NYSE: NVRO), a pioneer in neuromodulation therapies for chronic pain management, provides this centralized hub for investors and healthcare professionals to access its latest developments. Track official press releases, clinical milestones, and business updates from the creator of the Senza spinal cord stimulation system.
This resource delivers timely updates on NVRO's FDA clearances, international expansions, and evidence-based innovations like its AI-enhanced HFX platform. Users will find disclosures covering product launches, financial results, and strategic partnerships that shape chronic pain treatment globally.
Key updates include advancements in 10 kHz therapy clinical applications, regulatory approvals across markets, and operational developments impacting patient access. Bookmark this page to stay informed about Nevro's progress in redefining neuromodulation standards through engineering and clinical excellence.
Nevro Corp. (NYSE: NVRO), a leader in chronic pain treatment, announced that its Chairman and CEO, Keith Grossman, CFO Rod MacLeod, and CMO David Caraway will participate in the Wells Fargo 2022 MedTech R&D Spotlight Call Series on March 4, 2022, at 10:00 AM ET. The event will provide insights into Nevro's innovative solutions, including the proprietary 10 kHz Therapy. Investors can access a live webcast and archived recording on Nevro's website. For ongoing updates, Nevro encourages stakeholders to regularly visit their Investor Relations section.
Nevro Corp. (NYSE: NVRO) has published 12-month data from the SENZA-NSRBP randomized controlled trial in the Journal of Neurosurgery: Spine. The study highlights the effectiveness of high-frequency 10 kHz spinal cord stimulation (SCS) in treating non-surgical refractory back pain, showing that 78.2% of patients reported pain relief greater than 50%. The study involved 121 patients and demonstrated consistent safety, with a low explant rate of 2.1% and a significant 46% reduction in opioid use. Nevro is positioned uniquely with FDA approval for this therapy.
Nevro Corp. (NYSE: NVRO), a leader in chronic pain solutions, announced that its Chairman, CEO, and President, D. Keith Grossman, will present at Citi's 2022 Virtual Healthcare Conference on February 24, 2022, at 12:30 pm Eastern Time. A webcast will be available on their website. Nevro has developed the innovative 10 kHz Therapy, which has benefited over 80,000 patients globally, significantly impacting chronic pain treatment.
Nevro Corp. has responded to Medtronic's FDA approval for painful diabetic neuropathy (PDN), highlighting the significant market potential for this condition. The company asserts its SENZA-PDN trial is the largest and most comprehensive for spinal cord stimulation therapy, yielding superior outcomes compared to Medtronic's studies. Nevro claims its proprietary 10 kHz Therapy offers advantages in pain relief, treatment success rates, and neurological improvement. The company expresses concern over Medtronic's reliance on older studies for FDA approval, emphasizing the robust data from their SENZA-PDN trial.
Nevro Corp. (NYSE: NVRO), a medical device company, will announce its fourth quarter and full-year 2021 financial results on February 23, 2022. The report will be released after market close, followed by a conference call at 1:30 PM PT to discuss the results. Interested investors can access the call by dialing (888) 330-2443 or +1 (240) 789-2728 internationally, using Conference ID: 3583097. Nevro, based in Redwood City, California, specializes in chronic pain solutions and is known for its 10 kHz Therapy benefiting over 80,000 patients worldwide.
Nevro Corp. (NYSE: NVRO), based in Redwood City, California, has received FDA approval for expanded labeling of its Senza® Spinal Cord Stimulation (SCS) System to treat Non-Surgical Refractory Back Pain (NSRBP), marking it the only SCS system specifically indicated for this condition. This approval highlights Nevro's proprietary 10 kHz Therapy. Clinical trials indicate significant improvements in pain relief and quality of life for patients after 12 months of treatment. Nevro aims to enhance market access and payer coverage based on these results.
Nevro Corp. announced significant outcomes from its clinical trials presented at the 2022 North American Neuromodulation Society Annual Meeting. The SENZA-PDN trial demonstrated durable efficacy for 10 kHz spinal cord stimulation in painful diabetic neuropathy at 18 months, with no explants due to loss of efficacy. The SENZA-NSRBP trial showed profound pain relief and improved quality of life in patients at 12 months, supported by cost-effectiveness data for the treatment. Nevro aims to be the only SCS company with an on-label indication for treating non-surgical refractory back pain upon FDA approval.
Nevro Corp. (NYSE: NVRO) reported preliminary unaudited revenue results for Q4 and full-year 2021, expecting Q4 revenue of approximately $102.5 million, down from $109.7 million YoY. Full-year revenue is expected at $386.6 million, up from $362.0 million in 2020. Despite Q4 declines, U.S. trial procedures rose 3%, with painful diabetic neuropathy (PDN) trials growing 92% sequentially. Nevro anticipates exceeding its adjusted EBITDA guidance of negative $10 million to negative $13 million. The company plans to report full financial results on February 23, 2022.
Nevro Corp. (NYSE: NVRO) announced that UnitedHealthcare will provide coverage for its high-frequency 10 kHz Therapy for Painful Diabetic Neuropathy (PDN), effective March 1, 2022. This decision is seen as a major milestone in facilitating access to Nevro's FDA-approved spinal cord stimulation therapy. UnitedHealthcare’s policy considers this treatment medically necessary under specific criteria. Nevro believes this coverage will enhance its market position and lead to further endorsements from additional health plans, supported by extensive clinical data.
Nevro Corp. (NYSE: NVRO) announced a settlement of its patent lawsuit against Nalu Medical regarding high-frequency spinal cord stimulation (SCS) technology. Initially filed in February 2020, Nevro accused Nalu of patent infringement, but the lawsuit concluded with both parties agreeing to avoid further litigation costs. Nevro's General Counsel, Kashif Rashid, emphasized the importance of protecting intellectual property. Nevro remains the sole provider of FDA-approved high-frequency SCS therapy for painful diabetic neuropathy, allowing them to focus on developing solutions for chronic pain.
